These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35008095)

  • 1. Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells.
    Tan G; Wolski WE; Kummer S; Hofstetter M; Theocharides APA; Manz MG; Aebersold R; Meier-Abt F
    Blood Adv; 2022 Jun; 6(11):3480-3493. PubMed ID: 35008095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of hydroxyurea transporters in normal and polycythemia vera hematopoietic stem and progenitor cell subpopulations.
    Tan G; Meier-Abt F
    Exp Hematol; 2021 May; 97():47-56.e5. PubMed ID: 33677043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
    Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
    Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients.
    Bogeska R; Pahl HL
    Stem Cells Transl Med; 2013 Feb; 2(2):112-7. PubMed ID: 23341442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.
    Lu M; Wang X; Li Y; Tripodi J; Mosoyan G; Mascarenhas J; Kremyanskaya M; Najfeld V; Hoffman R
    Blood; 2012 Oct; 120(15):3098-105. PubMed ID: 22872685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
    Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in polycythemia vera and lessons for acute leukemia.
    Spivak JL
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101330. PubMed ID: 34865702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.
    Ishii T; Bruno E; Hoffman R; Xu M
    Blood; 2006 Nov; 108(9):3128-34. PubMed ID: 16757685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
    Vainchenker W; Constantinescu SN
    Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.
    Berkofsky-Fessler W; Buzzai M; Kim MK; Fruchtman S; Najfeld V; Min DJ; Costa FF; Bischof JM; Soares MB; McConnell MJ; Zhang W; Levine R; Gilliland DG; Calogero R; Licht JD
    Clin Cancer Res; 2010 Sep; 16(17):4339-52. PubMed ID: 20601445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
    Laubach JP; Fu P; Jiang X; Salter KH; Potti A; Arcasoy MO
    Exp Hematol; 2009 Dec; 37(12):1411-22. PubMed ID: 19815050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
    Wappl M; Jaeger E; Streubel B; Gisslinger H; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2008 Aug; 38(8):578-84. PubMed ID: 18717827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycythemia vera: the current status of preclinical models and therapeutic targets.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
    Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
    Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Austrian recommendations for the management of polycythemia vera.
    Burgstaller S; Buxhofer-Ausch V; Sliwa T; Beham-Schmid C; Gastl G; Geissler K; Melchardt T; Krauth M; Krippl P; Petzer A; Rumpold H; Wölfler A; Gisslinger H
    Wien Klin Wochenschr; 2018 Sep; 130(17-18):535-542. PubMed ID: 30027395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.